Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody- based therapies, today announced a partnership with ConjugateBio Inc. (ConjugateBio) to provide a proprietary antibody for use in partner companies' bispecific ADC development programs. "We have been very impressed with ...